English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The standard preparative regimen for autologous stem cell transplant (ASCT) in multiple myeloma (MM) is 200 mg/m 2  of intravenous melphalan; however, a dose of 140 mg/m 2  is often used when concerns exist related to patient age, performance status, organ function, and other factors. It is unclear whether a lower dose of melphalan impacts post-transplant survival outcomes. We performed a retrospective review of 930 patients with MM who underwent ASCT with 200 mg/m 2  versus 140 mg/m 2  melphalan. On univariable analysis, no difference in progression-free survival (PFS) was observed, however, an overall survival (OS) benefit was observed in patients receiving 200 mg/m 2  melphalan ( p  = 0.04). Multivariable analyses showed patients receiving 140 mg/m 2  faired no worse than those receiving 200 mg/m 2 . While a subset of younger patients with normal renal function may achieve superior OS with a standard dose of 200 mg/m 2  melphalan, these findings suggest an opportunity to individualize the ASCT preparative regimen to optimize outcomes.

leukemia and lymphoma

Survival outcomes following autologous stem cell transplant with melphalan 140mg/m 2  versus 200mg/m 2  preparative regimens in patients with multiple myeloma